Novel combinatorial autophagy inhibition therapy for triple negative breast cancers
Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved..
BACKGROUND: Triple negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes. It is characterized by lack of estrogen, progesterone and human epidermal growth factor 2 receptors, and thus, have limited therapeutic options. Autophagy has been found to be correlated with poor prognosis and aggressive behaviour in TNBC. This study aimed to target autophagy in TNBC via a novel approach to inhibit TNBC progression.
METHODS: Immunoblotting and confocal microscopy were carried out to examine the effect of tumor microenvironmental stressors on autophagy. Cellular proliferation and migration assays were used to test the effect of different autophagy inhibitors and standard chemotherapy alone or in combination. In vivo xenograft mouse model was utilized to assess the effect of autophagy inhibitors alone or in combination with Paclitaxel. High resolution mass spectrometry based proteomic analysis was performed to explore the mechanisms behind chemoresistance in TNBC. Lastly, immunohistochemistry was done to assess the correlation between autophagy related proteins and clinical characteristics in TNBC tissue specimens.
RESULTS: Metabolic stressors were found to induce autophagy in TNBC cell lines. Autophagy initiation inhibitors, SAR405 and MRT68921, showed marked synergy in their anti-proliferative activity in both chemosensitive and chemoresistant TNBC cell models. Paradoxically, positive expression of autophagosome marker LC3 was shown to be associated with better overall survival of TNBC patients.
CONCLUSION: In this study, a novel combination between different autophagy inhibitors was identified which inhibited tumor cell proliferation in both chemosensitive and chemoresistant TNBC cells and could result in development of a novel treatment modality against TNBC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:973 |
|---|---|
| Enthalten in: |
European journal of pharmacology - 973(2024) vom: 09. Apr., Seite 176568 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abd El-Aziz, Yomna S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autophagy |
|---|
| Anmerkungen: |
Date Revised 24.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.ejphar.2024.176568 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370938577 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370938577 | ||
| 003 | DE-627 | ||
| 005 | 20240425233925.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejphar.2024.176568 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM370938577 | ||
| 035 | |a (NLM)38604544 | ||
| 035 | |a (PII)S0014-2999(24)00256-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abd El-Aziz, Yomna S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel combinatorial autophagy inhibition therapy for triple negative breast cancers |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Triple negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes. It is characterized by lack of estrogen, progesterone and human epidermal growth factor 2 receptors, and thus, have limited therapeutic options. Autophagy has been found to be correlated with poor prognosis and aggressive behaviour in TNBC. This study aimed to target autophagy in TNBC via a novel approach to inhibit TNBC progression | ||
| 520 | |a METHODS: Immunoblotting and confocal microscopy were carried out to examine the effect of tumor microenvironmental stressors on autophagy. Cellular proliferation and migration assays were used to test the effect of different autophagy inhibitors and standard chemotherapy alone or in combination. In vivo xenograft mouse model was utilized to assess the effect of autophagy inhibitors alone or in combination with Paclitaxel. High resolution mass spectrometry based proteomic analysis was performed to explore the mechanisms behind chemoresistance in TNBC. Lastly, immunohistochemistry was done to assess the correlation between autophagy related proteins and clinical characteristics in TNBC tissue specimens | ||
| 520 | |a RESULTS: Metabolic stressors were found to induce autophagy in TNBC cell lines. Autophagy initiation inhibitors, SAR405 and MRT68921, showed marked synergy in their anti-proliferative activity in both chemosensitive and chemoresistant TNBC cell models. Paradoxically, positive expression of autophagosome marker LC3 was shown to be associated with better overall survival of TNBC patients | ||
| 520 | |a CONCLUSION: In this study, a novel combination between different autophagy inhibitors was identified which inhibited tumor cell proliferation in both chemosensitive and chemoresistant TNBC cells and could result in development of a novel treatment modality against TNBC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Autophagy | |
| 650 | 4 | |a Autophagy inhibitors | |
| 650 | 4 | |a Chemoresistance | |
| 650 | 4 | |a Triple negative breast cancer | |
| 700 | 1 | |a Toit-Thompson, Taymin du |e verfasserin |4 aut | |
| 700 | 1 | |a McKay, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Molloy, Mark P |e verfasserin |4 aut | |
| 700 | 1 | |a Stoner, Shihani |e verfasserin |4 aut | |
| 700 | 1 | |a McDowell, Betty |e verfasserin |4 aut | |
| 700 | 1 | |a Moon, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Sioson, Loretta |e verfasserin |4 aut | |
| 700 | 1 | |a Sheen, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Chou, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Gill, Anthony J |e verfasserin |4 aut | |
| 700 | 1 | |a Jansson, Patric J |e verfasserin |4 aut | |
| 700 | 1 | |a Sahni, Sumit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 973(2024) vom: 09. Apr., Seite 176568 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
| 773 | 1 | 8 | |g volume:973 |g year:2024 |g day:09 |g month:04 |g pages:176568 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2024.176568 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 973 |j 2024 |b 09 |c 04 |h 176568 | ||